Sancuso Patch
NDC Package 66220-637-31

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Sancuso (granisetron) patches is a medication used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). This formulation utilizes a patch delivery system. Marketed by Cumberland Pharmaceuticals Inc., this product is identified by NDC 66220-637 and is authorized under FDA application NDA022198.

Identification & Billing

NDC Package Code
66220-637-31
Package Description
168 h in 1 POUCH
Product Code
66220-637
11-Digit Billing Format
66220063731
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 825003 - granisetron 3.1 MG/Day 7 Day Transdermal System
  • RxCUI: 825003 - 168 HR granisetron 0.129 MG/HR Transdermal System
  • RxCUI: 825003 - granisetron 3.1 MG/Day Weekly Transdermal Patch
  • RxCUI: 825005 - Sancuso 3.1 MG/Day 7 Day Transdermal System
  • RxCUI: 825005 - 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso]

Clinical Specifications

Proprietary Name
Sancuso
Non-Proprietary Name
Granisetron
Substance Name
Granisetron
Dosage Form
Patch - A drug delivery system that often contains an adhesive backing that is usually applied to an external site on the body. Its ingredients either passively diffuse from, or are actively transported from, some portion of the patch. Depending upon the patch, the ingredients are either delivered to the outer surface of the body or into the body. A patch is sometimes synonymous with the terms ‘extended release film’ and ‘system’.
Administration Route
Transdermal - Administration through the dermal layer of the skin to the systemic circulation by diffusion.
Active Ingredient(s)
GRANISETRON 3.1 mg/24h
Pharmacologic Class
Usage Information
This medication is used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). It works by blocking one of the body's natural substances (serotonin) that can cause vomiting.

Regulatory & Marketing

Labeler Name
Cumberland Pharmaceuticals Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA022198
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-16-2024
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (66220-637). Click a package code to view its specific billing and regulatory data.

66220-637-72
168 h in 1 POUCH

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 66220-637-31 identifies a specific commercial package of 168 h in 1 pouch of Sancuso, a human prescription drug labeled by Cumberland Pharmaceuticals Inc.. This patch is formulated for transdermal use and contains granisetron as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cumberland Pharmaceuticals Inc. on July 16, 2024. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). It works by blocking one of the body's natural substances (serotonin) that can cause vomiting.

How is this Cumberland Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 66220063731. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
66220-637-31
11-Digit CMS (5-4-2)
66220-0637-31

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.